Objectives: We report results of subgroup analyses of bone mineral density (BMD) and bone turnover markers from a randomized, double-blind, placebo-controlled, phase II study of denosumab, an investigational RANKL inhibitor, in patients with rheumatoid arthritis (RA) concurrently receiving treatment with bisphosphonates or glucocorticoids.
Methods: Patients received subcutaneous placebo (n=75), denosumab 60mg (n=71), or denosumab 180mg (n=72) at baseline and 6 months. Assessments included dual X-ray absorptiometry scans of the lumbar spine and hip, serum type I C-telopeptide (sCTx-I), and serum procollagen 1N terminal peptide (P1NP).
Results: Denosumab treatment increased mean lumbar spine and hip BMD and reduced sCTx-I and P1NP versus placebo through 12 months, regardless of baseline BMD or marker levels or concomitant bisphosphonate or glucocorticoid use.
Conclusions: This study extends evidence that denosumab increases BMD and reduces bone turnover in patients with RA and may provide a new therapeutic option for reducing systemic bone loss in patients with RA.
Statistics from Altmetric.com
Review history and Supplementary material
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.